BRAF mutation testing in melanoma: results from a German observational multicenter study

Hartmann, Arndt; Schirmacher, Peter; Sterlacci, William; Koch, Winfried; Liesenfeld, David B.; Schif, Birgit; Garbe, Claus

doi:10.1007/s00428-018-2480-4

Cited by 1 publication

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, patients with stage III disease undergo less molecular testing than those with recurrent or stage IV disease, however, this is likely reflective of approval of targeted agents and immunotherapy over the study period for this cohort of patients. The overall rate of BRAF mutations identified within our data (43%) is consistent with that of previously published studies [3,4,19]. As expected, most patients younger than 30 years had a BRAF mutated tumor (83.3%), compared to a minority of patients older than 80 years (25.2%).…”

Section: Discussionsupporting

confidence: 92%

“…As expected, most patients younger than 30 years had a BRAF mutated tumor (83.3%), compared to a minority of patients older than 80 years (25.2%). A study by Hartmann et al ., [4] evaluating predictors of BRAF mutations concluded that age was the most important predictor of BRAF mutations found in melanomas.…”

Section: Discussionmentioning

confidence: 99%

“…An estimated 40-60% of advanced melanomas harbor a mutation in the BRAF gene, which is associated with the mitogen-activated protein kinase (MAPK) pathway [3,4]. Compared to wild-type tumors, this mutation is more likely seen in younger patients, those with superficial spreading or nodular histology and commonly leads to more aggressive behavior, including brain metastases [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma

Hill

Vidrí²,

Deng³

et al. 2022

Melanoma Research

View full text Add to dashboard Cite

Both BRAF/MEK targeted agents and immunotherapy are approved for the treatment of advanced melanoma. BRAF testing is recommended at the time of advanced melanoma diagnosis. In addition, little is known regarding the treatment trends for patients with BRAF mutated tumors. This investigation aims to assess the real-world prevalence of molecular testing and treatment trends for patients with BRAF mutated tumors. Using a de-identified database, patients of age ≥18 years with advanced melanoma from 2013 to 2018 were examined. Molecular testing performed within 3 months of advanced diagnosis was considered to have the test performed at the time of diagnosis. Test prevalence was calculated and compared in groups stratified by the patient, tumor and treatment factors. In total 4459 patients were included; 1936 (43.4%) stage III, 1191 (26.7%) stage IV and 1332 (29.9%) recurrent. Totally 50.4% of patients received systemic treatment; 76.4% stage IV, 71% recurrent patients and 26.7% stage III patients. However, 73.5% received first-line immunotherapy. In total 73.8% of patients had molecular testing, and 50.5% had tested at the time of advanced diagnosis. Of those tested 42% had a BRAF mutated tumor. In total 48% of these patients received first-line immunotherapy whereas 43% received a BRAF inhibitor, with increasing immunotherapy use seen over time. The majority of patients with advanced melanoma undergo molecular testing at the time of advanced diagnosis. Immunotherapy is the most commonly prescribed treatment regardless of BRAF mutational status. These results provide real-world data on the frequency of molecular testing and treatment trends for patients with advanced melanoma.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%